Stathmin is involved in the cooperative effect of Zoledronic acid and gefitinib on bone homing breast cancer cells in vitro

Zoledronic acid (Zol) is the most potent inhibitor of bone resorption among the bisphosphonates and is commonly used for inhibiting bone metastasis. However, it remains unclear whether Zol provides a survival benefit. Recent findings indicate that epidermal growth factor (EGF) signaling is an import...

Descripción completa

Detalles Bibliográficos
Autores principales: Oda, Miki, Iwaya, Keiichi, Kikuchi, Ryoko, Kobayashi, Takayuki, Yoneda, Toshiyuki, Nishikawa, Kahoko, Matsubara, Osamu, Kohno, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723330/
https://www.ncbi.nlm.nih.gov/pubmed/26909254
http://dx.doi.org/10.1016/j.jbo.2012.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723330/
https://www.ncbi.nlm.nih.gov/pubmed/26909254
http://dx.doi.org/10.1016/j.jbo.2012.06.001

Ejemplares similares